It found that between 2022 and 2023, as prescriptions for GLP-1 drugs more than doubled, rates of bariatric surgery fell by 25.6%. The findings, published Wednesday in JAMA Network Open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback